Cytek Biosciences, Inc. (NASDAQ:CTKB) Q2 2025 Earnings Call Transcript
Operator: Ladies and gentlemen, thank you for standing by. At this time, I would like to welcome everyone to the Cytek Biosciences Second Quarter 2025 Earnings Conference Call.
Cytek Biosciences Inc. (CTKB)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Hillhouse Capital Management Lei Zhang | 6,657,030 | $26,694,690 | 0.75% | |
| 2. | Topline Capital Collin Mcbirney | 1,470,775 | $5,897,808 | +522% | 1.35% |
| 3. | Renaissance Technologies Jim Simons | 687,600 | $2,757,276 | +49% | 0% |
| 4. | AQR Capital Management Cliff Asness | 653,277 | $2,619,640 | +395% | 0% |
| 5. | Citadel Investment Group Ken Griffin | 602,517 | $2,416,093 | +200% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.78 | 35,000 | $97,300.00 | 55,746 | 2025-06-02 | Filing | |
| $12.27 | 241,727 | $2,964,999.21 | 13,381,054 | 2022-03-15 | Filing | |
| $12.35 | 342,143 | $4,223,926.41 | 13,139,327 | 2022-03-14 | Filing | |
| $12.77 | 337,492 | $4,309,334.10 | 12,797,184 | 2022-03-11 | Filing | |
| $12.95 | 256,992 | $3,327,583.81 | 12,459,692 | 2022-03-10 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $5.87 | 20,000 | $117,400.00 | 5,988,502 | 2024-04-19 | Filing | |
| $7.01 | 400 | $2,804.00 | 6,008,502 | 2024-04-09 | Filing | |
| $7.00 | 1,500 | $10,500.00 | 6,008,902 | 2024-04-09 | Filing | |
| $6.71 | 20,000 | $134,200.00 | 6,010,402 | 2024-03-19 | Filing | |
| $6.77 | 20,000 | $135,400.00 | 6,030,402 | 2024-03-18 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 2,729,593 | $9,281,980 | 0% | |
| 2. | 699,913 | $2,379,704 | 0% | |
| 3. | 572,387 | $1,946,116 | 0% | |
| 4. | 319,066 | $1,084,824 | 0% | |
| 5. | 92,638 | $314,969 | 0% |
News See All
Cytek Biosciences, Inc. (CTKB): A Bull Case Theory
This stock is one of several featured in our latest research.
10 Promising SmallCap Stocks Under $1 Billion Market Cap
SmallCap stocks can often be overlooked by institutional investors, yet they offer outsized return potential for those willing to dig deeper.
Cytek Biosciences (CTKB) Faced Challenges from NIH Funding Reductions
Brown Capital Management, an investment management company, released its “The Brown Capital Management Small Company Fund” first quarter 2025 investor letter.
Cytek Biosciences, Inc. (CTKB) Elevates Cell Analysis with New Aurora Evo System
Cytek Biosciences, Inc. (NASDAQ:CTKB) has announced the launch of its latest innovation, the Cytek Aurora Evo system, marking a significant leap forward in flow cytometry technology.
Cytek Biosciences, Inc. (NASDAQ:CTKB) Q1 2025 Earnings Call Transcript
Operator: Thank you for standing by. At this time, I would like to welcome everyone to the Cytek Biosciences First Quarter 2025 Earnings Conference Call.
12 Cash-Rich Penny Stocks To Buy According To Hedge Funds
Shares priced under $5, commonly referred to as penny stocks, are a tempting bet for investors chasing big returns with minimal upfront investment.
Cytek Biosciences, Inc. (NASDAQ:CTKB) Q4 2024 Earnings Call Transcript
Operator: Thank you for standing by, and good day, everyone. My name is RG, and I will be your conference operator today.
Cytek Biosciences, Inc. (NASDAQ:CTKB) Q3 2024 Earnings Call Transcript
Operator: Thank you for standing by. At this time, I'd like to welcome everyone to the Cytek Biosciences' Third Quarter 2024 Earnings Conference Call.
Cytek Biosciences, Inc. (NASDAQ:CTKB) Q2 2024 Earnings Call Transcript
Operator: Thank you for standing by. My name is Luella, and I will be your conference operator today.